BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24011394)

  • 1. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
    Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
    Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
    Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.
    Guglielmi L; Cinnella C; Nardella M; Maresca G; Valentini A; Mercanti D; Felsani A; D'Agnano I
    Cell Death Dis; 2014 Feb; 5(2):e1081. PubMed ID: 24556696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Maeshima R; Moulding D; Stoker AW; Hart SL
    Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
    Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
    Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of MYCN expression in human neuroblastoma cells.
    Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
    BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
    Horvilleur E; Bauer M; Goldschneider D; Mergui X; de la Motte A; Bénard J; Douc-Rasy S; Cappellen D
    Nucleic Acids Res; 2008 Aug; 36(13):4222-32. PubMed ID: 18583365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.
    Wu PY; Liao YF; Juan HF; Huang HC; Wang BJ; Lu YL; Yu IS; Shih YY; Jeng YM; Hsu WM; Lee H
    PLoS One; 2014; 9(2):e88795. PubMed ID: 24586395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells.
    Chen B; Hua Z; Gong B; Tan X; Zhang S; Li Q; Chen Y; Zhang J; Li Z
    Life Sci; 2020 Sep; 256():117820. PubMed ID: 32512012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
    Yamaguchi Y; Takenobu H; Ohira M; Nakazawa A; Yoshida S; Akita N; Shimozato O; Iwama A; Nakagawara A; Kamijo T
    Eur J Cancer; 2014 May; 50(8):1555-65. PubMed ID: 24559687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
    Liu Z; Yang X; Li Z; McMahon C; Sizer C; Barenboim-Stapleton L; Bliskovsky V; Mock B; Ried T; London WB; Maris J; Khan J; Thiele CJ
    Cell Death Differ; 2011 Jul; 18(7):1174-83. PubMed ID: 21252912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.